Literature DB >> 9619773

Aerosol delivery of lipid:DNA complexes to lungs of rhesus monkeys.

R J McDonald1, H D Liggitt, L Roche, H T Nguyen, R Pearlman, O G Raabe, L B Bussey, C M Gorman.   

Abstract

PURPOSE: The potential use of aerosol delivery for non-viral gene therapy was tested by nebulization of lipid:DNA complexes to the lungs of rhesus monkeys.
METHODS: Four female rhesus monkeys were dosed with lipid:DNA formulations via aerosol inhalation, where the DNA coded for the human Cystic Fibrosis Transmembrane Conductance Regulator (hCFTR) protein. Delivery of DNA was determined in lung samples by polymerase chain reaction (PCR) by qualitative and quantitative methods. Transgene specific messenger RNA was measured by reverse transcriptase PCR (RT-PCR) and protein expression and localization were evaluated by immunohistochemistry (IHC).
RESULTS: Approximately four mg of DNA, complexed with cationic lipid 1.2-dimyristoyl-sn-glycero-3-ethylphosphatidylcholine (EDMPC) and cholesterol were delivered to the lungs of animals by airjet nebulizer. Three days after dosing, tissue samples from the lung were collected and shown to have vector specific DNA, RNA and the presence of CFFR protein. Specifically, the hCFTR protein was distributed widely, although non-uniformly, throughout airway epithelium being located on the apical surface of epithelial cells. Importantly, no adverse clinical effects were observed and the lungs showed no histological abnormalities or signs of acute inflammation.
CONCLUSIONS: This study shows that lipid:DNA formulations based on EDMPC and cholesterol can be administered to primates by nebulization resulting in measurable expression of the hCFTR protein. The absence of inflammation is also encouraging and such systems may have utility for delivery of genes to the lungs for the treatment of a variety of pulmonary diseases including cystic fibrosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9619773     DOI: 10.1023/a:1011902532163

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  17 in total

1.  Plasmid DNA molecules complexed with cationic liposomes are protected from degradation by nucleases and shearing by aerosolisation.

Authors:  K Crook; G McLachlan; B J Stevenson; D J Porteous
Journal:  Gene Ther       Date:  1996-09       Impact factor: 5.250

Review 2.  Current status of CF gene therapy.

Authors:  R C Boucher
Journal:  Trends Genet       Date:  1996-03       Impact factor: 11.639

3.  Activation of the major immediate early gene of human cytomegalovirus by cis-acting elements in the promoter-regulatory sequence and by virus-specific trans-acting components.

Authors:  M F Stinski; T J Roehr
Journal:  J Virol       Date:  1985-08       Impact factor: 5.103

4.  A demonstration using mouse models that successful gene therapy for cystic fibrosis requires only partial gene correction.

Authors:  J R Dorin; R Farley; S Webb; S N Smith; E Farini; S J Delaney; B J Wainwright; E W Alton; D J Porteous
Journal:  Gene Ther       Date:  1996-09       Impact factor: 5.250

5.  Intratracheal gene delivery to the mouse airway: characterization of plasmid DNA expression and pharmacokinetics.

Authors:  K B Meyer; M M Thompson; M Y Levy; L G Barron; F C Szoka
Journal:  Gene Ther       Date:  1995-09       Impact factor: 5.250

6.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.

Authors:  J R Riordan; J M Rommens; B Kerem; N Alon; R Rozmahel; Z Grzelczak; J Zielenski; S Lok; N Plavsic; J L Chou
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

7.  Aerosol and intravenous transfection of human alpha 1-antitrypsin gene to lungs of rabbits.

Authors:  A E Canonico; J T Conary; B O Meyrick; K L Brigham
Journal:  Am J Respir Cell Mol Biol       Date:  1994-01       Impact factor: 6.914

8.  Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy.

Authors:  S C Hyde; D R Gill; C F Higgins; A E Trezise; L J MacVinish; A W Cuthbert; R Ratcliff; M J Evans; W H Colledge
Journal:  Nature       Date:  1993-03-18       Impact factor: 49.962

9.  Non-invasive liposome-mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice.

Authors:  E W Alton; P G Middleton; N J Caplen; S N Smith; D M Steel; F M Munkonge; P K Jeffery; D M Geddes; S L Hart; R Williamson
Journal:  Nat Genet       Date:  1993-10       Impact factor: 38.330

10.  Cationic lipids for reporter gene and CFTR transfer to rat pulmonary epithelium.

Authors:  J J Logan; Z Bebok; L C Walker; S Peng; P L Felgner; G P Siegal; R A Frizzell; J Dong; M Howard
Journal:  Gene Ther       Date:  1995-01       Impact factor: 5.250

View more
  9 in total

1.  Aerosolization of lipoplexes using AERx Pulmonary Delivery System.

Authors:  Deepa Deshpande; James Blanchard; Sudarshan Srinivasan; Dallas Fairbanks; Jun Fujimoto; Teiji Sawa; Jeanine Wiener-Kronish; Hans Schreier; Igor Gonda
Journal:  AAPS PharmSci       Date:  2002

2.  Preparation and characterization of poly (D,L-lactide-co-glycolide) microspheres for controlled release of poly(L-lysine) complexed plasmid DNA.

Authors:  Y Capan; B H Woo; S Gebrekidan; S Ahmed; P P DeLuca
Journal:  Pharm Res       Date:  1999-04       Impact factor: 4.200

3.  Cell targeting in anti-cancer gene therapy.

Authors:  Mohd Azmi Mohd Lila; John Shia Kwong Siew; Hayati Zakaria; Suria Mohd Saad; Lim Shen Ni; Jafri Malin Abdullah
Journal:  Malays J Med Sci       Date:  2004-01

Review 4.  Novel molecular approaches to cystic fibrosis gene therapy.

Authors:  Tim W R Lee; David A Matthews; G Eric Blair
Journal:  Biochem J       Date:  2005-04-01       Impact factor: 3.857

5.  Studies of the structure and organization of cationic lipid bilayer membranes: calorimetric, spectroscopic, and x-ray diffraction studies of linear saturated P-O-ethyl phosphatidylcholines.

Authors:  R N Lewis; I Winter; M Kriechbaum; K Lohner; R N McElhaney
Journal:  Biophys J       Date:  2001-03       Impact factor: 4.033

6.  Highly efficient cationic ethylphosphatidylcholine siRNA carrier for GFP suppression in modified breast cancer cells.

Authors:  Boris Tenchov; Yasuro Sugimoto; Rumiana Koynova; Robert W Brueggemeier; Robert J Lee
Journal:  Anticancer Res       Date:  2012-07       Impact factor: 2.480

Review 7.  Cystic Fibrosis Gene Therapy: Looking Back, Looking Forward.

Authors:  Ashley L Cooney; Paul B McCray; Patrick L Sinn
Journal:  Genes (Basel)       Date:  2018-11-07       Impact factor: 4.096

8.  Gene Therapy: A Possible Alternative to CFTR Modulators?

Authors:  J Mercier; M Ruffin; H Corvol; L Guillot
Journal:  Front Pharmacol       Date:  2021-04-21       Impact factor: 5.810

Review 9.  Delivery systems for pulmonary gene therapy.

Authors:  Ajay Gautam; Clifford J Waldrep; Charles L Densmore
Journal:  Am J Respir Med       Date:  2002
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.